Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773278 · ClinicalTrials.gov registry record · Phase 2
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
A Phase 2 study of Hearing Loss and Smith-Lemli-Opitz Syndrome, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT01773278: Recruiting Phase 2 study of Hearing Loss and Smith-Lemli-Opitz Syndrome, sponsored by University of Colorado, Denver.
NCT01773278 is a Phase 2 study of Hearing Loss and Smith-Lemli-Opitz Syndrome that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 100 participants, below the 6,119-participant average among 58 other Hearing Loss trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01773278, a Phase 2 study of Hearing Loss and Smith-Lemli-Opitz Syndrome, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with biochemically confirmed SLOS are being treated with cholesterol supplementation and antioxidant medication. They are carefully monitored with visits to clinic, laboratory testing including cholesterol and 7-dehydrocholesterol levels, vitamin levels, blood counts and liver and kidney function. On a serial basis, no more often than once a year, the patients undergo a series of tests under anesthesia, including electroretinogram (ERG), brainstem audiometry (ABR), and ophthalmologic exam under anesthesia to follow pigmentary retinopathy.
Conditions Studied
Interventions
- DRUG Antioxidants
- DRUG Cholesterol
Study Locations (1)
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-12 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What NCT01773278 shows while recruiting
NCT01773278 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 6,119-participant average among 58 other Hearing Loss trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Antioxidants is the first listed.
NCT01773278 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT01773278 about?
NCT01773278 is a clinical study titled "Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)". Patients with biochemically confirmed SLOS are being treated with cholesterol supplementation and antioxidant medication. They are carefully monitored with visits to clinic, laboratory testing including cholesterol and 7-dehydrocholesterol levels, vitamin levels, blood counts and liver and kidney fu...
What is the current status of trial NCT01773278?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2008-12. Estimated completion is 2025-12.
What conditions does trial NCT01773278 study?
This clinical trial studies the following conditions: Hearing Loss, Smith-Lemli-Opitz Syndrome, Cone-Rod Dystrophy.
What interventions are being tested in trial NCT01773278?
The interventions under investigation include: Antioxidants (DRUG), Cholesterol (DRUG).
Who is sponsoring clinical trial NCT01773278?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01773278 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01773278's enrollment target sits among peer trials
100 30th of 58 higher than 28 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
RECRUITING · Phase 2
-
SPI-1005 in Adults Receiving Cochlear Implant
RECRUITING · Phase 2
-
Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
COMPLETED · Phase 2
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia